Home › Epilepsy › New Jersey › Clifton
Epilepsy clinical trials in Clifton, NJ
4 studies for Epilepsy are looking for participants at sites in and around Clifton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
RecruitingPhase 3
- Northeast Regional Epilepsy Group, Hackensack · 7 mi away
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
RecruitingPhase 3
- Northeast Regional Epilepsy Group, Hackensack · 7 mi away
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RecruitingPhase 3
- Northeast Regional Epilepsy Group, Hackensack · 7 mi away
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
RecruitingPhase 1/2
- Northeast Regional Epilepsy Group, Hackensack · 7 mi away
About Epilepsy
Epilepsy is a brain disorder that causes people to have seizures. The seizures may be mild or severe. Learn about causes, diagnosis, and treatment.
More about Epilepsy on MedlinePlus
Epilepsy trials in other cities
- Boston, MA18 studies
- Houston, TX15 studies
- New York City, NY14 studies
- Washington, DC13 studies
- Philadelphia, PA12 studies
- Durham, NC9 studies
- Phoenix, AZ9 studies
- Rochester, MN9 studies
- Cleveland, OH9 studies
- Miami, FL8 studies
- Birmingham, AL7 studies
- Mountain View, CA6 studies
Other studies in Clifton
- Non-Small Cell Lung Cancer23 studies
- Multiple Myeloma15 studies
- Cancer (all types)13 studies
- Prostate Cancer12 studies
- Acute Myeloid Leukemia11 studies
- Ovarian Cancer11 studies
- Metastatic Cancer11 studies
- Breast Cancer11 studies
- Colorectal Cancer9 studies
- Lung Cancer9 studies
- Heart Failure9 studies
- Leukemia8 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.